Identification

Name
Canagliflozin
Accession Number
DB08907
Type
Small Molecule
Groups
Approved
Description

Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.

Structure
Thumb
Synonyms
  • Canagliflozin anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Canagliflozin hydrate0SAC974Z85928672-86-0VHOFTEAWFCUTOS-TUGBYPPCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InvokanaTablet100 mgOralJanssen Pharmaceuticals2014-06-03Not applicableCanada
InvokanaTablet, film coated100 mg/1OralJanssen Pharmaceuticals2013-03-29Not applicableUs50458 0140 90 nlmimage10 4744a395
InvokanaTablet300 mgOralJanssen Pharmaceuticals2014-05-28Not applicableCanada
InvokanaTablet, film coated300 mg/1OralJanssen Pharmaceuticals2013-03-29Not applicableUs50458 0141 30 nlmimage10 a344d186
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
InvokametCanagliflozin (150 mg) + Metformin Hydrochloride (850 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
InvokametCanagliflozin (50 mg) + Metformin Hydrochloride (500 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
InvokametCanagliflozin (50 mg/1) + Metformin Hydrochloride (1000 mg/1)Tablet, film coatedOralJanssen Pharmaceuticals2014-08-08Not applicableUs
InvokametCanagliflozin (150 mg) + Metformin Hydrochloride (500 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
InvokametCanagliflozin (150 mg/1) + Metformin Hydrochloride (1000 mg/1)Tablet, film coatedOralJanssen Pharmaceuticals2014-08-08Not applicableUs
InvokametCanagliflozin (50 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralJanssen Pharmaceuticals2014-08-08Not applicableUs
InvokametCanagliflozin (50 mg) + Metformin Hydrochloride (850 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
InvokametCanagliflozin (50 mg) + Metformin Hydrochloride (1000 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
InvokametCanagliflozin (150 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralJanssen Pharmaceuticals2014-08-08Not applicableUs
InvokametCanagliflozin (150 mg) + Metformin Hydrochloride (1000 mg)TabletOralJanssen Pharmaceuticals2016-06-28Not applicableCanada
Categories
UNII
6S49DGR869
CAS number
842133-18-0
Weight
Average: 444.516
Monoisotopic: 444.140672805
Chemical Formula
C24H25FO5S
InChI Key
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1

Pharmacology

Indication

Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.

Associated Conditions
Pharmacodynamics

Canagliflozin binds to SGLT2 more potently (250-times) than SGLT1 in vitro. The 50% inhibitory concentrations (IC50) are 2.2-4.4 nmol/L and 684 - 910 nmol/L for SGLT2 and SGLT1 respectively. Dose dependent decreases in renal threshold for glucose and increases in urinary glucose excretion were observed when single and multiple oral doses were administered to type 2 diabetes patients. Decreases in plasma glucose in a dose-dependent fashion were also noted as early as the first day of administration. When given to healthy and type 2 diabetic patients before a meal, a delay in intestinal glucose absorption and a reduction in postprandial glucose was observed. Canagliflozin does not prolong the QTc interval.

Mechanism of action

Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.

TargetActionsOrganism
ASodium/glucose cotransporter 2
inhibitor
Human
USodium/glucose cotransporter 1
inhibitor
Human
Absorption

The pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. Accumulation in plasma has been observed following multiple doses of 100 - 300 mg. Food does not affect the absorption of canagliflozin. Tmax = 1- 2 hours; Cmax = 1059 - 3148 ng/mL; Time to steady state, once daily dose, 100 - 300 mg = 4-5 days; Absolute oral bioavailability = 65%.

Volume of distribution

Steady state, single IV infusion, healthy subject = 119 L. This high value suggests that cangliflozin is extensively distributed to tissue.

Protein binding

>99% protein bound, mainly to albumin. It also binds to alpha-acid glycoprotein. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.

Metabolism

Canagliflozin is hepatically metabolized via O-glucuronidation into two inactive O-glucuronide metabolites. The enzymes that facilitate this process are UGT1A9 and UGT2B4. To a lesser extent (7%), canagliflozin also undergoes oxidative metabolism via CYP3A4. Canagliflozin weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on in vitro studies with human hepatic microsomes.

Route of elimination

Enterohepatic circulation of canagliflozin was negligible. When a single oral dose is administered to a healthy subject, canagliflozin is eliminated via the following: Feces (41.5%, 7.0%, 3.2% as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively). Urine (33%; 30.5% as O-glucuronide metabolite, <1% as unchanged drug).

Half life

The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.

Clearance

Mean systemic clearance, healthy subjects, IV administration = 192 mL/min. Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

Toxicity

Most common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Canagliflozin.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.Approved, Investigational
AcetaminophenThe serum concentration of Canagliflozin can be increased when it is combined with Acetaminophen.Approved
AcetohexamideCanagliflozin may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Canagliflozin can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Canagliflozin.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Canagliflozin.Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Canagliflozin.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.Approved
AliskirenCanagliflozin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AloxiprinAloxiprin may increase the hypoglycemic activities of Canagliflozin.Experimental
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.Approved, Investigational
AmilorideCanagliflozin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Canagliflozin.Approved
AmiodaroneThe serum concentration of Canagliflozin can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Canagliflozin can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Canagliflozin.Approved, Illicit
AmphetamineAmphetamine may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.Approved
ApalutamideThe serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Canagliflozin.Approved
AprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Canagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Canagliflozin.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Canagliflozin.Approved, Investigational
ArticaineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Canagliflozin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Canagliflozin.Approved
AtomoxetineThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.Approved
Azilsartan medoxomilCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
AzosemideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Azosemide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Canagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Canagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Canagliflozin.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
BenazeprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
BenzthiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Benzthiazide.Approved
Benzyl alcoholThe serum concentration of Canagliflozin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Canagliflozin.Approved, Investigational
BisacodylThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bisacodyl.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.Approved
BoceprevirThe metabolism of Canagliflozin can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Canagliflozin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Canagliflozin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.Approved
BrexpiprazoleThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Canagliflozin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Canagliflozin.Approved, Investigational
BumetanideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.Approved, Investigational
BuserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.Approved, Investigational
CaffeineThe serum concentration of Canagliflozin can be increased when it is combined with Caffeine.Approved
CandesartanCanagliflozin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilCanagliflozin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CandoxatrilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Captopril.Approved
CarbamazepineThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Canagliflozin.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Canagliflozin.Approved, Investigational
CarbutamideCanagliflozin may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Canagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.Approved
CarvedilolThe serum concentration of Canagliflozin can be increased when it is combined with Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Canagliflozin can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Canagliflozin.Approved, Investigational, Vet Approved
ChlorpropamideCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe risk or severity of hypotension can be increased when Canagliflozin is combined with Chlorthalidone.Approved
CilazaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Canagliflozin.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Canagliflozin.Approved, Investigational
CinoxacinCinoxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Withdrawn
CiprofloxacinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Canagliflozin.Approved
ClarithromycinThe metabolism of Canagliflozin can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Canagliflozin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Canagliflozin.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Approved
ClotrimazoleThe metabolism of Canagliflozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Canagliflozin.Approved
CobicistatThe metabolism of Canagliflozin can be decreased when combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Canagliflozin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Canagliflozin.Approved, Investigational
CorticotropinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Canagliflozin can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Canagliflozin can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Canagliflozin.Approved
CyclopenthiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Canagliflozin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.Approved
DabrafenibThe serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Canagliflozin.Approved
DanazolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Canagliflozin.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Canagliflozin.Investigational
DarunavirThe metabolism of Canagliflozin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Canagliflozin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Delapril.Investigational
DelavirdineThe metabolism of Canagliflozin can be decreased when combined with Delavirdine.Approved
DersalazineDersalazine may increase the hypoglycemic activities of Canagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.Approved
DesogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Canagliflozin.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.Approved, Vet Approved
DexniguldipineThe serum concentration of Canagliflozin can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Canagliflozin can be increased when it is combined with Dexverapamil.Experimental
DiazoxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.Approved, Investigational
DienogestThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
DihydroergotamineThe metabolism of Canagliflozin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Canagliflozin can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.Approved
DisopyramideCanagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
DocusateThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Docusate.Approved
DoxazosinThe serum concentration of Canagliflozin can be increased when it is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.Approved, Investigational
DoxycyclineThe metabolism of Canagliflozin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Canagliflozin can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.Approved
DuloxetineCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.Approved
EfavirenzThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Canagliflozin.Approved, Investigational
EmopamilThe serum concentration of Canagliflozin can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.Approved
EnzalutamideThe serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpitizideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epitizide.Experimental
EplerenoneCanagliflozin may increase the hyperkalemic activities of Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.Approved
EprosartanCanagliflozin may increase the hyperkalemic activities of Eprosartan.Approved
ErythromycinThe metabolism of Canagliflozin can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Canagliflozin.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Canagliflozin.Approved
Ethynodiol diacetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Canagliflozin.Withdrawn
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.Approved
FelodipineThe serum concentration of Canagliflozin can be increased when it is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Canagliflozin.Approved
FentanylThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FimasartanCanagliflozin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FleroxacinFleroxacin may increase the hypoglycemic activities of Canagliflozin.Approved
FluconazoleThe metabolism of Canagliflozin can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
FluoxetineThe serum concentration of Canagliflozin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Canagliflozin.Approved
FluvoxamineThe serum concentration of Canagliflozin can be increased when it is combined with Fluvoxamine.Approved, Investigational
ForasartanCanagliflozin may increase the hyperkalemic activities of Forasartan.Experimental
FosamprenavirThe metabolism of Canagliflozin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Canagliflozin can be increased when it is combined with Gallopamil.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
GlibornurideCanagliflozin may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideCanagliflozin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCanagliflozin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCanagliflozin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneCanagliflozin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideCanagliflozin may increase the hypoglycemic activities of Glisoxepide.Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Canagliflozin.Investigational
GlyburideCanagliflozin may increase the hypoglycemic activities of Glyburide.Approved
GlycerinThe serum concentration of Canagliflozin can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.Approved
Gramicidin DThe serum concentration of Canagliflozin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Canagliflozin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.Approved, Vet Approved
HarmalineHarmaline may increase the hypoglycemic activities of Canagliflozin.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Canagliflozin.Experimental
HeparinHeparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Canagliflozin.Approved
HistrelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Canagliflozin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.Approved
HydrochlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IbuprofenThe serum concentration of Canagliflozin can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe metabolism of Canagliflozin can be decreased when combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.Approved, Investigational
ImatinibThe metabolism of Canagliflozin can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Canagliflozin.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Canagliflozin.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.Approved
IndinavirThe metabolism of Canagliflozin can be decreased when combined with Indinavir.Approved
Insulin AspartCanagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCanagliflozin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCanagliflozin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCanagliflozin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCanagliflozin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCanagliflozin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkCanagliflozin may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Canagliflozin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Canagliflozin.Withdrawn
IrbesartanCanagliflozin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Canagliflozin.Approved, Investigational
IsavuconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Canagliflozin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Canagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Canagliflozin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Canagliflozin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Canagliflozin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.Approved
LacidipineCanagliflozin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactuloseThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Lactulose.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Canagliflozin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Canagliflozin.Approved, Investigational
LanreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Canagliflozin.Approved, Investigational
LeuprolideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Canagliflozin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Canagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Canagliflozin.Approved, Investigational
LevodopaCanagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Canagliflozin.Approved, Investigational
LidocaineThe serum concentration of Canagliflozin can be increased when it is combined with Lidocaine.Approved, Vet Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Nutraceutical
LisinoprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Canagliflozin.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
LomerizineThe serum concentration of Canagliflozin can be increased when it is combined with Lomerizine.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Canagliflozin.Approved
LopinavirThe metabolism of Canagliflozin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Canagliflozin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of hyperkalemia and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.Approved
LovastatinThe metabolism of Canagliflozin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.Approved, Investigational
MecaserminCanagliflozin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Canagliflozin can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Canagliflozin.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Canagliflozin.Experimental
MestranolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Mestranol.Approved
MetahexamideCanagliflozin may increase the hypoglycemic activities of Metahexamide.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Canagliflozin.Approved
MethotrimeprazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Canagliflozin.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Canagliflozin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Canagliflozin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.Approved
MetolazoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Canagliflozin.Approved, Investigational
MibefradilThe metabolism of Canagliflozin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Canagliflozin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
MinaprineMinaprine may increase the hypoglycemic activities of Canagliflozin.Approved
Mineral oilThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Mineral oil.Approved, Vet Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.Approved, Investigational
MitotaneThe serum concentration of Canagliflozin can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
MoexiprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Canagliflozin.Approved, Investigational
MoxifloxacinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Canagliflozin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.Approved
NandroloneNandrolone may increase the hypoglycemic activities of Canagliflozin.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit
NateglinideCanagliflozin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.Approved, Investigational
NefazodoneThe metabolism of Canagliflozin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Canagliflozin can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Canagliflozin.Approved, Investigational
NetupitantThe serum concentration of Canagliflozin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Canagliflozin can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Canagliflozin.Withdrawn
NicardipineThe serum concentration of Canagliflozin can be increased when it is combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Canagliflozin.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Canagliflozin.Approved
NiguldipineThe serum concentration of Canagliflozin can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Canagliflozin can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Canagliflozin.Approved, Investigational
NimodipineThe serum concentration of Canagliflozin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Canagliflozin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Canagliflozin.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Canagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Canagliflozin.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
NorgestimateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.Approved, Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Canagliflozin.Approved, Investigational
OctamoxinOctamoxin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
OctreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
OlanzapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Canagliflozin can be decreased when combined with Olaparib.Approved
OlmesartanCanagliflozin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Canagliflozin.Approved
OmapatrilatThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Canagliflozin.Approved
OsimertinibThe serum concentration of Canagliflozin can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Canagliflozin.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Canagliflozin.Approved
OxycodoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Canagliflozin.Approved, Illicit
OxymorphoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.Approved, Vet Approved
PalbociclibThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.Approved, Investigational
PargylinePargyline may increase the hypoglycemic activities of Canagliflozin.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
ParoxetineThe serum concentration of Canagliflozin can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Canagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Canagliflozin.Approved, Investigational
PentamidineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Canagliflozin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerindoprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Canagliflozin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
PhenobarbitalThe serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Canagliflozin.Approved
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Canagliflozin.Approved
PhenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Canagliflozin.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Canagliflozin.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Canagliflozin.Experimental
PiperazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.Approved, Investigational
PiretanideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Piretanide.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Canagliflozin.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Canagliflozin.Experimental
PitolisantThe serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
PolythiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.Approved
PosaconazoleThe metabolism of Canagliflozin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Potassium Chloride.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Canagliflozin.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Canagliflozin.Approved, Illicit, Investigational
PrimidoneThe serum concentration of Canagliflozin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Canagliflozin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Canagliflozin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Canagliflozin.Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Canagliflozin.Approved
QuinaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Canagliflozin is combined with Quinethazone.Approved
QuinineCanagliflozin may increase the hypoglycemic activities of Quinine.Approved
RamiprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.Approved
RanitidineThe serum concentration of Canagliflozin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Canagliflozin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canagliflozin.Approved
RepaglinideCanagliflozin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Canagliflozin.Approved, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Canagliflozin.Approved, Investigational
RifabutinThe metabolism of Canagliflozin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Canagliflozin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Riociguat.Approved
RisperidoneCanagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Canagliflozin can be decreased when it is combined with Ritonavir.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Canagliflozin.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.Approved
RucaparibThe metabolism of Canagliflozin can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Canagliflozin.Experimental
SacubitrilCanagliflozin may increase the hyperkalemic activities of Sacubitril.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved
SaprisartanCanagliflozin may increase the hyperkalemic activities of Saprisartan.Experimental
SaquinavirThe metabolism of Canagliflozin can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinCanagliflozin may increase the hyperkalemic activities of Saralasin.Investigational
SarilumabThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Canagliflozin.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.Approved, Vet Approved
SildenafilThe metabolism of Canagliflozin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.Approved
SiltuximabThe serum concentration of Canagliflozin can be decreased when it is combined with Siltuximab.Approved, Investigational
Silver sulfadiazineThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimeprevirThe serum concentration of Canagliflozin can be increased when it is combined with Simeprevir.Approved
SirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Canagliflozin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Canagliflozin.Approved, Investigational
Sodium phosphate, monobasicCanagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
SpiraprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Spirapril.Approved
SpironolactoneCanagliflozin may increase the hyperkalemic activities of Spironolactone.Approved
St. John's WortThe serum concentration of Canagliflozin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hypoglycemic activities of Canagliflozin.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Canagliflozin.Approved, Vet Approved
StiripentolThe serum concentration of Canagliflozin can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.Approved, Investigational
SulfadiazineCanagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Canagliflozin.Approved
SulfisoxazoleThe metabolism of Canagliflozin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Canagliflozin.Approved, Investigational
SunitinibCanagliflozin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Canagliflozin.Approved, Investigational
TasosartanCanagliflozin may increase the hyperkalemic activities of Tasosartan.Approved
TelaprevirThe metabolism of Canagliflozin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Canagliflozin can be decreased when combined with Telithromycin.Approved
TelmisartanCanagliflozin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Canagliflozin.Withdrawn
TemocaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Temocapril.Experimental, Investigational
TemsirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Canagliflozin.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Canagliflozin.Approved
Testosterone propionateTestosterone propionate may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Canagliflozin.Approved, Vet Approved
TetrandrineThe serum concentration of Canagliflozin can be increased when it is combined with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Canagliflozin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.Approved, Withdrawn
TiclopidineThe metabolism of Canagliflozin can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Canagliflozin.Approved
TinzaparinTinzaparin may increase the hyperkalemic activities of Canagliflozin.Approved
TipranavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.Approved, Investigational
TocilizumabThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.Approved
TolazamideCanagliflozin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Canagliflozin.Approved, Vet Approved
TolbutamideCanagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Canagliflozin.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Canagliflozin.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Canagliflozin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Canagliflozin.Approved, Investigational
TorasemideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.Approved
TramadolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Canagliflozin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneCanagliflozin may increase the hyperkalemic activities of Triamterene.Approved
TrichlormethiazideThe risk or severity of hypotension can be increased when Canagliflozin is combined with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Canagliflozin.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Canagliflozin.Approved, Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Canagliflozin can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
ValsartanCanagliflozin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Canagliflozin.Approved
VemurafenibThe serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Canagliflozin.Approved
VerapamilThe serum concentration of Canagliflozin can be increased when it is combined with Verapamil.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Canagliflozin.Approved, Investigational
VoriconazoleThe metabolism of Canagliflozin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Canagliflozin.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Canagliflozin.Withdrawn
ZiprasidoneThe metabolism of Canagliflozin can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413]
External Links
KEGG Drug
D09592
PubChem Compound
24812758
PubChem Substance
175427146
ChemSpider
26333259
BindingDB
50386885
ChEBI
73274
ChEMBL
CHEMBL2048484
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Canagliflozin
ATC Codes
A10BD16 — Metformin and canagliflozinA10BX11 — Canagliflozin
AHFS Codes
  • 68:20.18 — Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
FDA label
Download (683 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers7
1CompletedNot AvailableHealthy Volunteers / Hepatic Insufficiency1
1CompletedOtherHealthy Volunteers2
1CompletedTreatmentBioequivalence1
1CompletedTreatmentHealthy Volunteers24
1CompletedTreatmentHealthy Volunteers / Impaired Renal Function1
1CompletedTreatmentPlasma Volume / Type 2 Diabetes Mellitus1
1CompletedTreatmentType 2 Diabetes Mellitus7
1Enrolling by InvitationBasic ScienceType 2 Diabetes Mellitus1
1RecruitingOtherDiabetes Mellitus (DM) / Fibroblast Growth Factor (FGF23) / Phosphate / PTH / Vitamin D1
1, 2CompletedTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentBMI >30 kg/m22
2CompletedTreatmentDiabetes Mellitus, Non Insulin Dependent / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentType 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus1
3CompletedTreatmentCardiovascular Disease (CVD) / Risk Factors / Type 2 Diabetes Mellitus1
3CompletedTreatmentImpaired Renal Function / Type 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus14
3RecruitingTreatmentDiabetic Nephropathies1
3RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedTreatmentAlbuminuria / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus3
4Enrolling by InvitationBasic ScienceAcute Gouty Arthritis / Diabetes Mellitus (DM) / Hyperuricemia1
4RecruitingTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4RecruitingTreatmentChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentHeart Failure, Systolic / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus5
4RecruitingTreatmentType II Diabetes in Subjects BMI 27 to 32 / Type II Diabetes in the Not so Obese1
4WithdrawnBasic ScienceCardiovascular Disease (CVD) / Type2 Diabetes Mellitus1
4WithdrawnTreatmentDiabetes, Obesity1
Not AvailableActive Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingNot AvailableType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingBasic ScienceHeart Failure, Unspecified / Type2 Diabetes1
Not AvailableRecruitingNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Tablet, film coated, extended releaseOral
TabletOral100 mg
TabletOral300 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral300 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723340No2001-10-252021-10-25Us
US8222219No2004-07-302024-07-30Us
US8513202No2007-12-032027-12-03Us
US7943582No2009-02-262029-02-26Us
US8785403No2004-07-302024-07-30Us
US7943788No2007-07-142027-07-14Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP3.09ALOGPS
logP3.52ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.15 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.14 m3·mol-1ChemAxon
Polarizability46.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9541
Blood Brain Barrier+0.7708
Caco-2 permeable-0.6554
P-glycoprotein substrateSubstrate0.6058
P-glycoprotein inhibitor INon-inhibitor0.8414
P-glycoprotein inhibitor IINon-inhibitor0.9447
Renal organic cation transporterNon-inhibitor0.8544
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8293
CYP450 3A4 substrateNon-substrate0.5929
CYP450 1A2 substrateNon-inhibitor0.6579
CYP450 2C9 inhibitorNon-inhibitor0.6178
CYP450 2D6 inhibitorNon-inhibitor0.8683
CYP450 2C19 inhibitorNon-inhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.7086
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7691
Ames testNon AMES toxic0.584
CarcinogenicityNon-carcinogens0.9103
BiodegradationNot ready biodegradable0.9936
Rat acute toxicity2.5975 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.7246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Hexoses / C-glycosyl compounds / Toluenes / Fluorobenzenes / 2,5-disubstituted thiophenes / Oxanes / Aryl fluorides / Heteroaromatic compounds / Secondary alcohols / Polyols
show 5 more
Substituents
Phenolic glycoside / Hexose monosaccharide / C-glycosyl compound / 2,5-disubstituted thiophene / Toluene / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Monocyclic benzene moiety
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, thiophenes, ring assembly, C-glycosyl compound (CHEBI:73274)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glucose:sodium symporter activity
Specific Function
Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a...
Gene Name
SLC5A1
Uniprot ID
P13866
Uniprot Name
Sodium/glucose cotransporter 1
Molecular Weight
73497.275 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da

Drug created on June 17, 2013 00:21 / Updated on August 15, 2018 09:55